Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Whole metagenome sequencing: not deep enough for complete microbial function recovery.

Microbiome·2026

Same author

Mental Health and Survival in Medicare Beneficiaries With Lung and Head and Neck Cancer.

Psycho-oncology·2026

Same author

CD38⁺ endothelial remodeling marks spatially patterned vasculopathy in rapidly advancing periodontitis and peri-implantitis.

Nature communications·2026

Same author

Population-level prevalence and risk of oral HPV infection with or without HPV vaccination.

Human vaccines & immunotherapeutics·2026

Same author

Cumulative Incidence and Risk of Depression After Opioid Use in Head and Neck Cancer Patients.

Head & neck·2026

Same author

An interpretable deep learning framework for predictive modeling of postoperative infections in ICU patients.

PloS one·2026

Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026

Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026

Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026

Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026

Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026

Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 6, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

Pradham Tanikella¹, William Nenad², Christophe Courtine³

¹Department of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

|March 14, 2026

Summary

This summary is machine-generated.

The GARD pipeline identifies new drug repurposing candidates for head and neck cancer (HNC) by analyzing genomic data and protein networks. This approach aids in discovering targeted therapies for personalized HNC treatment.

Keywords:

drug repurposing genomics head and neck cancer

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

Related Experiment Videos

Last Updated: May 6, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

Area of Science:

Oncology
Genomics
Bioinformatics

Background:

Head and neck cancer (HNC) has limited treatment improvements.
Drug repurposing offers a cost-effective strategy for new HNC therapies.
Existing treatments for HNC show suboptimal patient outcomes.

Purpose of the Study:

To develop the GARD pipeline for identifying HNC drug repurposing candidates.
To leverage genomic alterations and network-based approaches for drug discovery.
To uncover novel therapeutic options for head and neck cancer.

Main Methods:

Integrated multi-omics data (CNV, SOM) from TCGA, stratified by HPV status.
Identified risk genes and expanded them using protein-protein interaction (PPI) networks.
Validated gene-HNC associations using PubMed literature and LLMs, then mapped genes to DrugBank.

Main Results:

Identified significant HNC risk genes (e.g., PIK3CA, SOX2, TP53) across HPV subgroups.
Network expansion revealed additional targetable genes (e.g., EGFR, ERBB2, FGFRs).
Drug mapping identified clinical trial drugs and novel repurposing candidates (e.g., Afatinib, Amuvatinib, Aspirin).

Conclusions:

The GARD pipeline provides a systematic, genomics-driven framework for HNC drug repurposing.
HPV stratification and literature validation enhance precision and confidence in identified candidates.
This approach facilitates personalized treatment strategies by refining existing therapies and discovering new ones.